ClinicalTrials.gg
Status unknownNCT03394131Updated Jul 13, 2018

ُEfficacy of Insulin Versus Hyalase Hydro-dissection of Median Nerve in Rheumatoid Arthritis Patients

An interventional study of Hylase and Insulin in Treatment Resistant Carpal Tunnel in RA Patients, sponsored by Assiut University. Status unknown at 1 site in Egypt. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-07-13.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2017, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

Carpal tunnel syndrome (CTS) is a common peripheral entrapment neuropathy in Rheumatoid arthritis patients proved by nerve conduction studies and ultrasound parameters, this study aims to evaluate the effect of hydro-dissection using insulin versus hyalase versus saline, ultrasounic guided as an effective treatment

Read the detailed description

Carpal tunnel syndrome (CTS) is a common peripheral entrapment neuropathy in Rheumatoid arthritis patients proved by nerve conduction studies and ultrasound parameters, this study aims to evaluate the effect of hydro-dissection of median nerve inside CT twice injections with interval 2 weeks using insulin and 10 cc saline versus hyalase and 10 cc saline versus 10 cc saline, ultrasounic guided as an effective treatment of CT

02

Conditions studied

  • Treatment Resistant Carpal Tunnel in RA Patients
03

In context

Lead sponsor

Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Rheumatoid arthritis in remission

Exclusion criteria

Exclusion Criteria:

  • active Rheumatoid arthritis
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Hyalase

    injection and hydro-dissection of median nerve using hyaluronidase followed by 10 cc normal saline ultrasonic guided

    Drug: Hylase

  • Placebo comparator
    Placebo

    injection and hydro-dissection of median nerve hydro-dissection using 10 cc saline injection ultrasonic guided

    Other: saline

  • Active comparator
    Insilin

    injection and hydro-dissection of median nerve hydro-dissection using 10 IU insuline followed by 10 cc normal saline ultrasonic guided

    Drug: Insulin

Interventions

  • DrugHylase

    hydro-dissection injection of median nerve inside carpal tunnel using hyalase and 10 cc saline

    Also known as: Hyaluronidase

  • hydro-dissection injection of median nerve inside carpal tunnel using 10 IU insulin and 10 cc saline

    Also known as: crystalline insulin

  • Othersaline

    hydro-dissection injection of median nerve inside carpal tunnel using 10 cc saline

    Also known as: normal saline

06

What researchers measure

Primary outcomes

  1. pain intensity

    Visual analog scale 0-100

    Time frame: 6 months

Secondary outcomes

  1. nerve conduction

    sensory velocity

    Time frame: 6 months

  2. ultrasound

    cross sectional area

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — after complete recruiting of patients

Supporting information: Study protocol

Time frame: 1 year

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in May 2018, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2017
First posted
Jan 9, 2018
StartActual
Jul 1, 2017
Primary completionActual
May 1, 2018
CompletionEst.
Aug 1, 2018
Last update
Jul 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03394131
Lead sponsor
Assiut University
Responsible party
Manal Hassanien (principle investigaror, Assiut University) — Principal investigator
First posted
Jan 9, 2018
Start date
Jul 1, 2017
Primary completion
May 1, 2018
Completion
Aug 1, 2018 (estimated)
Last update
Jul 13, 2018

Study contacts

Manal Hassanien, MD
Contact
manal_hassanien@yahoo.com
01062679200
Abdelraheem Elawamy, MD
Contact
arawamyyy@yahoo.com
01000032655
Manal Hassanien, MD
principal investigator · Assiut University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hylase

Start the discussion